{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:20:13Z","timestamp":1787541613335,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10620-026-09785-x","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:33:50Z","timestamp":1774589630000},"page":"3667-3675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The SILVER Platter for Patients with Inflammatory Bowel Disease (IBD): An IBD Pharmacy Technician-Led Subcutaneous Biologic Home Delivery Service Is Associated with Sustained Improvement in Adherence and Active Health Management"],"prefix":"10.1007","volume":"71","author":[{"given":"Andrew","family":"Leake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng Wei","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalgleish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Inserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleiman","family":"Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chellaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9149-3589","authenticated-orcid":false,"given":"Mayur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"9785_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time Based on Systematic Review. Gastroenterology. 2012;142:46-54.e42.","journal-title":"Gastroenterology."},{"key":"9785_CR2","doi-asserted-by":"crossref","unstructured":"Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real\u2010world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review. J Clin Pharm Ther. 2019 Mar 14;jcpt.12830.","DOI":"10.1111\/jcpt.12830"},{"key":"9785_CR3","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.3390\/jcm11247296","volume":"11","author":"C Remy","year":"2022","unstructured":"Remy C, Caron B, Gouynou C, Haghnejad V, Jeanbert E, Netter P et al. Inflammatory Bowel Disease Patients\u2019 Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. J Clin Med. 2022;11:7296.","journal-title":"J Clin Med."},{"key":"9785_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/ibd\/izy102","volume":"24","author":"BJ Wentworth","year":"2018","unstructured":"Wentworth BJ, Buerlein RCD, Tuskey AG, Overby MA, Smolkin ME, Behm BW. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24:2053\u20132061.","journal-title":"Inflamm Bowel Dis."},{"key":"9785_CR5","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","volume":"19","author":"A Lopez","year":"2013","unstructured":"Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2013;19:1528\u20131533.","journal-title":"Inflamm Bowel Dis."},{"key":"9785_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5217\/ir.2017.15.4.434","volume":"15","author":"W Chan","year":"2017","unstructured":"Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017;15:434.","journal-title":"Intest Res."},{"key":"9785_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/pharmacy13010021","volume":"13","author":"K King","year":"2025","unstructured":"King K, Czuber-Dochan W, Chalder T, Norton C. Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention. Pharmacy. 2025;13:21.","journal-title":"Pharmacy."},{"key":"9785_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s12325-009-0069-7","volume":"26","author":"SV Kane","year":"2009","unstructured":"Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn\u2019s disease patients. Adv Ther. 2009;26:936\u2013946.","journal-title":"Adv Ther."},{"key":"9785_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ajg.2017.438","volume":"113","author":"SM Govani","year":"2018","unstructured":"Govani SM, Noureldin M, Higgins PDR, Heisler M, Saini SD, Stidham RW et al. Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. Am J Gastroenterol. 2018;113:276\u2013282.","journal-title":"Am J Gastroenterol."},{"key":"9785_CR10","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.3399\/BJGP.2022.0351","volume":"73","author":"DC Butler","year":"2023","unstructured":"Butler DC, Joshy G, Douglas KA, Bin Sayeed MS, Welsh J, Douglas A et al. Changes in general practice use and costs with COVID-19 and telehealth initiatives: analysis of Australian whole-population linked data. British Journal of General Practice. 2023;73:e364\u2013e373.","journal-title":"British Journal of General Practice."},{"key":"9785_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.dld.2025.04.032","volume":"57","author":"A Dal Buono","year":"2025","unstructured":"Dal Buono A, Armuzzi A, Caprioli F, Castiglione F, Danese S, Gionchetti P et al. Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus. Digestive and Liver Disease. 2025;57:1403\u20131410.","journal-title":"Digestive and Liver Disease."},{"key":"9785_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11096-022-01470-z","volume":"45","author":"S Hyvert","year":"2023","unstructured":"Hyvert S, Yailian AL, Haesebaert J, Vignot E, Chapurlat R, Dussart C et al. Association between health literacy and medication adherence in chronic diseases: a recent systematic review. Int J Clin Pharm. 2023;45:38\u201351.","journal-title":"Int J Clin Pharm."},{"key":"9785_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/8755122515572809","volume":"31","author":"NK Kadia","year":"2015","unstructured":"Kadia NK, Schroeder MN. Community Pharmacy-Based Adherence Programs and the Role of Pharmacy Technicians. Journal of Pharmacy Technology. 2015;31:51\u201357.","journal-title":"Journal of Pharmacy Technology."},{"key":"9785_CR14","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571\u20131578.","journal-title":"Am J Gastroenterol."},{"key":"9785_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1186\/1471-2458-13-658","volume":"13","author":"RH Osborne","year":"2013","unstructured":"Osborne RH, Batterham RW, Elsworth GR, Hawkins M, Buchbinder R. The grounded psychometric development and initial validation of the Health Literacy Questionnaire (HLQ). BMC Public Health. 2013;13:658.","journal-title":"BMC Public Health."},{"key":"9785_CR16","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.8371","volume":"20","author":"L Kayser","year":"2018","unstructured":"Kayser L, Karnoe A, Furstrand D, Batterham R, Christensen KB, Elsworth G et al. A Multidimensional Tool Based on the eHealth Literacy Framework: Development and Initial Validity Testing of the eHealth Literacy Questionnaire (eHLQ). J Med Internet Res. 2018;20:e36.","journal-title":"J Med Internet Res."},{"key":"9785_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29\u201332.","journal-title":"Gut."},{"key":"9785_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"315","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s-disease activity. The Lancet. 1980;315:514.","journal-title":"The Lancet."},{"key":"9785_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691\u2013705.","journal-title":"Br J Clin Pharmacol."},{"key":"9785_CR20","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/ecco-jcc\/jjy083","volume":"12","author":"M van der Have","year":"2018","unstructured":"van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RCH, van Tuyl BA et al. Corrigendum: Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. J Crohns Colitis. 2018;12:1381\u20131381.","journal-title":"J Crohns Colitis."},{"key":"9785_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ibd\/izz253","volume":"26","author":"NB Shah","year":"2020","unstructured":"Shah NB, Haydek J, Slaughter J, Ashton JR, Zuckerman AD, Wong R et al. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:314\u2013320.","journal-title":"Inflamm Bowel Dis."},{"key":"9785_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3111\/13696998.2014.950669","volume":"17","author":"BG Feagan","year":"2014","unstructured":"Feagan BG, Kozma CM, Slaton TL, Olson WH, Wan GJ. Healthcare costs for Crohn\u2019s disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence. J Med Econ. 2014;17:872\u2013880.","journal-title":"J Med Econ."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09785-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09785-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09785-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:00:12Z","timestamp":1787540412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09785-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9785"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09785-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MG has served on the advisory board of Abbvie, Pfizer, and Ferring and has received speaker fees, research, or travel grants from Abbvie, Celltrion, Dr Falk, Ferring, Fresenius Kabi, Janssen, Pfizer, and Takeda.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}